The addition of intraperitoneal (IP) dwell chemotherapy to CRS and IV chemotherapy has been shown to delay recurrence in patients with "minimal residual disease" (<1 cm diameter residual tumor nodules) after surgery, but more importantly it has been shown to increase long-term (10-year) cure rates in patients with "no residual macroscopic disease" after surgery. Data from randomized trials of IP dwell chemotherapy demonstrate median survival of 49-66 months and 5-and 10-year survival rates of 40-60% in patients with "no residual macroscopic disease" after surgery, while those with "minimal residual disease" achieve improved short-term survival (median survival 53 months and 5-year survival rate 45%), while 10-year survival remains lower (18%). [5] [6] [7] [8] 10, 11 However, IP dwell chemotherapy has not been widely adopted due to complexity of administration, logistical issues, IP-catheter associated complications, poor patient compliance, and poor tolerance due to increased toxicity. 10, 12 Given the challenges and lack of acceptance of IP dwell chemotherapy, hyperthermic intraperitoneal chemoperfusion (HIPEC) has been evaluated in advanced stage III ovarian cancer with the aim to eliminate residual microscopic disease and thereby reduce disease recurrence and prolong survival. HIPEC is now widely performed following maximal CRS to treat peritoneal metastases from appendix cancer, colorectal cancer, and malignant peritoneal mesothelioma and this combination has demonstrated survival benefit. [13] [14] [15] The benefits of HIPEC over IP dwell chemotherapy include 1) single treatment at the time of surgery with high-dose chemotherapeutic agents (20-1000-fold higher drug concentration); 2) direct cytotoxicity of hyperthermia; 3) synergistic enhancement of chemotherapeutic effect by hyperthermia; and 4) intraoperative administration without the need for IP-catheter placement or postoperative IP treatments. 16, 17 CRS-HIPEC has been evaluated as first-line therapy for ovarian PM in several small prospective phase I-II studies and some retrospective case series. These data demonstrate median survival of 27-78 months (weighted mean 37.6 months) and 5-year survival rates of 28-72%
(weighted mean 40%). [18] [19] [20] [21] [22] [23] However, current consensus statements by international gynecologic cancer groups and the National Comprehensive Cancer Networks (NCCN) do not advocate for HIPEC as a standard therapeutic option for primary ovarian PM. A number of international randomized trials of CRS-HIPEC are currently ongoing to evaluate its utility in advanced primary or recurrent ovarian cancer. 19 Locoregional ovarian cancer recurrence confined to the peritoneal cavity occurs in over 65% of patients within 5-years, despite excellent response rates to maximal front-line multimodality therapy. 6 All factors that were examined in univariate analysis were considered for entry into the model for multivariate analysis.
Variables were selected for the final multivariate model based a combination of selection methods. platinum-sensitive disease; 11 patients (22.5%) had platinum-resistant disease, and 1 patient (2%) had platinum-refractory disease (Table 1) .
Multiple drug regimens were administered for residual or recurrent disease to 50 patients (52.1%) prior to undergoing CRS-HIPEC at our institution. One patient underwent three HIPEC procedures at our institution, another had two, while one patient had undergone CRS-HIPEC prior to being treated at our institution. Similar to previous publications, residual disease following CRS-HIPEC was an independent predictor of poor survival in this study of patients with OPM and PPC. 9, 25, [34] [35] [36] The negative impact of residual tumor nodules has been extensively reported for ovarian cancer and has led to a paradigm shift in surgical approach from "optimal CRS" being defined as <1 cm residual disease "minimal residual disease" after surgery to total macroscopic clearance "no residual visible disease." 37 | 325
The extent of peritoneal tumor burden has been shown to influence the ability to achieve complete macroscopic resection. 35 Since the vast majority of advanced ovarian cancers are high-grade serous carcinomas that are highly sensitive to systemic chemotherapy, preoperative systemic chemotherapy has been advocated to optimize resection, especially in patients with high tumor burden. 39, 40 Two randomized control trials demonstrated non-inferiority of shortcourse neoadjuvant IV chemotherapy prior to CRS compared to upfront surgery with adjuvant IV chemotherapy in patients with stage IIIC and IV OPM and PPC. 41, 42 Conversely, several published observational studies demonstrate worse survival in patients receiving neoadjuvant IV chemotherapy. [43] [44] [45] While selection bias may account for this discrepancy (since patients with borderline resectable disease and those with heavier disease burden may be more likely to receive neoadjuvant IV chemotherapy), the potential for selecting chemoresistant clones that are less obvious at surgical exploration may also lead to earlier recurrence and worse survival. 10 Current NCCN guidelines recommend neoadjuvant IV chemotherapy only for patients with high-volume disease who are not surgical candidates. In our study, the use of preoperative IV chemotherapy and response to chemotherapy did not influence survival. In addition, we did not demonstrate significant survival difference between patients with platinum-sensitive versus platinum-resistant/refractory disease, which is in accordance with the larger multi-institutional analysis conducted by Bakrin et al. 46 Histopathologic subtype was an independent predictor of survival in our study. This is not surprising given that the various subtypes of ovarian cancer have been shown to have distinct predisposing risk factors, genetic aberrations, and altered cellular signaling pathways that influence their response to therapy and oncologic outcomes. 37, 47 Consistent with published data, our study demonstrated better survival for mucinous borderline, low-grade serous carcinoma and endometrioid carcinoma, compared to those with high-grade serous carcinoma, clear cell carcinoma and carcinosarcoma. Finally, postoperative morbidity was an independent predictor of survival in our study and is consistent with prior studies of CRS-HIPEC for a variety of malignancies. 48 This underscores the importance of balancing the potential benefits of aggressive multimodality therapy with the inherent risks associated with CRS-HIPEC. Moreover, our data would suggest against the use of cisplatin perfusion over mitomycin C given the lack of survival benefit and potential increased postoperative morbidity with cisplatin. In our study, Clavien-Dindo grade 3-4 renal complications occurred in three patients receiving cisplatin in the perfusate. These three renal complications occurred earlier in our series when we were using higher doses of cisplatin based on a phase 1 trial of HIPEC with cisplatin conducted by one of our authors while at the NIH (National Institute of Health) that demonstrated a maximum tolerated dose of 250 mg/m 2 . 49 We serially reduced the cisplatin dose This includes maintenance of urine output above 200 ml/h during the operation and for the first 12 h postoperatively, followed by a urine output of 100 ml/h for the next 12 h; as well as administration of sodium thiosulfate bolus and 12 h continuous infusion that starts prior to cisplatin perfusion. Though mitomycin has not shown significant efficacy via intravenous route in epithelial ovarian cancer, its use in cytoreductive surgery/HIPEC derives from regimens for gastrointestinal malignancies. At our institution, treatment with a platinumcontaining agent is preferred for patients with platinum-sensitive EOC; however, it is more toxic than mitomycin C, particularly in regards to renal dysfunction. In patients who are known to be platinum-resistant or in whom performance status, medical comorbidities, or end-organ disease prohibit the use of a platinum-containing agent, mitomycin C is preferred. Our institution has previously shown success using mitomycin C for epithelial ovarian cancer patients.
Limitations of our study include the relatively small sample size, heterogeneity of the patient population and inherent bias associated with the retrospective nature of the data. There is also some missing data, especially for analysis regarding use of and response to preoperative IV chemotherapy, as well as platinum-sensitivity that may have biased the results. Finally, we can only infer any potential benefit from the addition of HIPEC to multimodality therapy since direct comparison to standard therapy (CRS + IV chemotherapy ± IP chemotherapy) was not performed.
| CONCLUSIONS
In conclusion, our data demonstrate promising survival results in patients with primary or recurrent OPM and PPC undergoing CRS-HIPEC. The addition of HIPEC to standard multimodality therapy allows for regional delivery of chemotherapy, while overcoming some of the logistical issues and complications associated with IP dwell chemotherapy that have prevented its widespread use. Results from ongoing randomized trials of CRS-HIPEC for primary and recurrent OPM and PPC will clarify the role of this aggressive locoregional approach.
